We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Peptide Biomarker Predicts Risk of Dying in Patients with Stable Heart Failure

By LabMedica International staff writers
Posted on 13 Jan 2020
Cardiovascular disease researchers have identified a biomarker that predicts when a patient with chronic stable heart failure (CHF) is likely to die.

Individuals with stable CHF have suffered damage to their heart muscles but do not usually require hospitalization. More...
While these individuals are at increased risk of dying within five years from the time of injury, some experience rapid disease progression while others remain in a stable condition.

Investigators at the University of California, Los Angeles (USA) searched for biomarkers that could distinguish between these two classes of CHF patients. To this end, they analyzed blood samples from 105 patients with stable heart failure, searching for a distinct biomarker in the blood that could predict how likely a person would be to die within a few years. The investigators examined coronary sinus (CS) blood in a prospective cohort of patients with stable CHF at the time of elective cardiac resynchronization therapy (CRT) device implantation, during which the CS was readily accessible. Coronary sinus blood was chosen for sampling over peripheral venous blood to avoid the potential contaminating effect of other tissues such as the gastrointestinal tract. The mean age of the patients was 68 years and 82 (78%) were men.

Results revealed that neuropeptide Y levels were the clearest and most significant predictor of which patients were most likely to die within one to three years. Neuropeptide Y (NPY) is a 36 amino-acid neuropeptide that is involved in various physiological and homeostatic processes in both the central and peripheral nervous systems. NPY has been identified as the most abundant peptide present in the mammalian central nervous system, which consists of the brain and spinal cord. It is secreted alongside other neurotransmitters such as GABA and glutamate.

Overall, findings obtained during this study indicated that patients with higher levels of neuropeptide Y were nearly 10 times more likely to die within one to three years than those with lower levels of NPY. Thus, determination of NPY level could serve as a tool to distinguish very-high-risk patients with stable heart failure from lower risk patients with the same condition. This information would identify those patients requiring more aggressive and targeted therapies.

The study was published in the December 26, 2019, online edition of the journal JAMA Cardiology.

Related Links:
University of California, Los Angeles


New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
Pipette
Accumax Smart Series
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.